通过膜转运蛋白/受体的当前前药策略。

Current prodrug strategies via membrane transporters/receptors.

作者信息

Anand Banmeet S, Dey Surajit, Mitra Ashim K

机构信息

Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 5005 Rockhill Road, Kansas City, Missouri 64110-2499, USA.

出版信息

Expert Opin Biol Ther. 2002 Aug;2(6):607-20. doi: 10.1517/14712598.2.6.607.

Abstract

Prodrug design strategies have been employed to improve the delivery of drugs with undesirable pharmacokinetic properties such as chemical stability and lack of specificity. Targeted prodrug design represents a new strategy for site-directed and efficient drug delivery. Targeting of drugs to transporters and receptors to aid in site-specific carrier-mediated absorption is emerging as a novel and clinically significant approach. Various prodrugs have been successful in achieving the goals of enhanced bioavailability and are, therefore, considered to be an important tool in biopharmaceutics. This review highlights the advances in prodrug design targeted towards membrane transporters/receptors in the past few years.

摘要

前体药物设计策略已被用于改善具有不良药代动力学性质(如化学稳定性差和缺乏特异性)的药物的递送。靶向前体药物设计是一种用于定点和高效药物递送的新策略。将药物靶向转运体和受体以辅助位点特异性载体介导的吸收正在成为一种新颖且具有临床意义的方法。各种前体药物已成功实现提高生物利用度的目标,因此被认为是生物药剂学中的一种重要工具。本综述重点介绍了过去几年中针对膜转运体/受体的前体药物设计的进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索